Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2017 1
2018 3
2019 1
2020 3
2021 3
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
EULAR definition of difficult-to-treat rheumatoid arthritis.
Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, Bijlsma HW, Zink A, Aletaha D, Schoneveld L, van Riel P, Gutermann L, Prior Y, Nikiphorou E, Ferraccioli G, Schett G, Hyrich KL, Mueller-Ladner U, Buch MH, McInnes IB, van der Heijde D, van Laar JM. Nagy G, et al. Among authors: gutermann l. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344. Epub 2020 Oct 1. Ann Rheum Dis. 2021. PMID: 33004335 Free PMC article.
Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus.
Gossec L, Molto A, Romand X, Puyraimond-Zemmour D, Lavielle M, Beauvais C, Senbel E, Flipo RM, Pouplin S, Richez C, Saraux A, Mézières M, Gutermann L, Gaudin P, Wendling D, Dougados M. Gossec L, et al. Among authors: gutermann l. Joint Bone Spine. 2019 Jan;86(1):13-19. doi: 10.1016/j.jbspin.2018.08.006. Epub 2018 Sep 19. Joint Bone Spine. 2019. PMID: 30243782 Free article. Review.
Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice.
Lauret A, Moltó A, Abitbol V, Gutermann L, Conort O, Chast F, Goulvestre C, Le Jeunne C, Chaussade S, Roux C, Batteux F, Dougados M, Allanore Y, Avouac J. Lauret A, et al. Among authors: gutermann l. Semin Arthritis Rheum. 2020 Dec;50(6):1449-1456. doi: 10.1016/j.semarthrit.2020.02.007. Epub 2020 Feb 19. Semin Arthritis Rheum. 2020. PMID: 32268935
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.
Avouac J, Moltó A, Abitbol V, Etcheto A, Salcion A, Gutermann L, Klotz C, Elhai M, Cohen P, Soret PA, Morin F, Conort O, Chast F, Goulvestre C, Jeunne CL, Chaussade S, Kahan A, Roux C, Allanore Y, Dougados M. Avouac J, et al. Among authors: gutermann l. Semin Arthritis Rheum. 2018 Apr;47(5):741-748. doi: 10.1016/j.semarthrit.2017.10.002. Epub 2017 Oct 5. Semin Arthritis Rheum. 2018. PMID: 29102156